AbbVie
ABBV
#25
Rank
NZ$700.95 B
Marketcap
NZ$396.61
Share price
-0.66%
Change (1 day)
35.27%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Market capitalization of AbbVie (ABBV)

Market cap: NZ$700.95 Billion

As of December 2025 AbbVie has a market cap of NZ$700.95 Billion. This makes AbbVie the world's 25th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of AbbVie from 2012 to 2025

End of year Market Cap

Year Marketcap Change
2025NZ$700.95 B25.67%
2024NZ$557.77 B28.92%
2023NZ$432.64 B-3.89%
2022NZ$450.15 B28.45%
2021NZ$350.44 B33.67%
2020NZ$262.17 B34.84%
2019NZ$194.42 B-4.34%
2018NZ$203.24 B-6.51%
2017NZ$217.38 B47.97%
2016NZ$146.91 B5.43%
2015NZ$139.34 B4.84%
2014NZ$132.91 B30.29%
2013NZ$102.01 B55.48%
2012NZ$65.60 B

End of Day market cap according to different sources

On Dec 4th, 2025 the market cap of AbbVie was reported to be:

NZ$700.61 Billion
by Nasdaq info icon info icon
NZ$700.95 Billion
by CompaniesMarketCap info icon info icon

Market capitalization for similar companies or competitors

Name Marketcap Market cap differencediff. Country
Pfizer
PFE
NZ$253.39 B-63.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$183.39 B-73.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$1.577 T 124.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$317.63 B-54.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$263.83 B-62.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$46.29 B-93.40%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$170.01 B-75.75%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
NZ$484.06 B-30.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$26.66 B-96.20%๐Ÿ‡บ๐Ÿ‡ธ USA